1. Swerdlow, SH, Campo, E, Harris, NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Rev 4th ed. Lyon: IARC, 2017.
Google Scholar2. Morrison, VA, Shou, Y, Bell, JA, et al. Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA. Future Oncol 2019; 15: 1021–1034.
Google Scholar | Crossref | Medline3. Friedberg, JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology 2011; 2011: 498–505.
Google Scholar | Crossref | Medline4. International Non-Hodgkin’s Lymphoma Prognostic Factors Project . A predictive model for aggressive non-Hodgkin’s lymphoma. New Engl J Med 1993; 329: 987–994.
Google Scholar | Crossref | Medline5. Sehn, LH, Berry, B, Chhanabhai, M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109: 1857–1861.
Google Scholar | Crossref | Medline | ISI6. Ziepert, M, Hasenclever, D, Kuhnt, E, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28: 2373–2380.
Google Scholar | Crossref | Medline | ISI7. Alizadeh, AA, Eisen, MB, Davis, RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511.
Google Scholar | Crossref | Medline | ISI8. Rosenwald, A, Wright, G, Chan, WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. New Engl J Med 2002; 346: 1937–1947.
Google Scholar | Crossref | Medline | ISI9. Lenz, G, Wright, G, Dave, SS, et al. Stromal gene signatures in large-B-cell lymphomas. New Engl J Med 2008; 359: 2313–2323.
Google Scholar | Crossref | Medline | ISI10. Gutiérrez-García, G, Cardesa-Salzmann, T, Climent, F, et al. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood 2011; 117: 4836–4843.
Google Scholar | Crossref | Medline | ISI11. Jais, JP, Haioun, C, Molina, TJ, et al. The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. Leukemia 2008; 22: 1917–1924.
Google Scholar | Crossref | Medline12. Rimsza, LM, LeBlanc, ML, Unger, JM, et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood 2008; 112: 3425–3433.
Google Scholar | Crossref | Medline | ISI13. Rimsza, LM, Wright, G, Schwartz, M, et al. Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues. Clin Cancer Res 2011; 17: 3727–3732.
Google Scholar | Crossref | Medline14. Barrans, SL, Crouch, S, Care, MA, et al. Whole genome expression profiling based on paraffin embedded tissue can be used to classify diffuse large B-cell lymphoma and predict clinical outcome. Br J Haematol 2012; 159: 441–453.
Google Scholar | Crossref | Medline15. Masqué-Soler, N, Szczepanowski, M, Kohler, CW, et al. Molecular classification of mature aggressive B-cell lymphoma using digital multiplexed gene expression on formalin-fixed paraffin-embedded biopsy specimens. Blood 2013; 122: 1985–1986.
Google Scholar | Crossref | Medline16. Scott, DW, Wright, GW, Williams, PM, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 2014; 123: 1214–1217.
Google Scholar | Crossref | Medline17. Jais, JP, Molina, TJ, Ruminy, P, et al. Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay. Haematologica 2017; 102: e404–e406.
Google Scholar | Crossref18. Vitolo, U, Trneˇný, M, Belada, D, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol 2017; 35: 3529–3537.
Google Scholar | Crossref | Medline19. Scott, DW, Mottok, A, Ennishi, D, et al. Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol 2015; 33: 2848–2856.
Google Scholar | Crossref | Medline20. Hans, CP, Weisenburger, DD, Greiner, TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275–282.
Google Scholar | Crossref | Medline | ISI21. Read, JA, Koff, JL, Nastoupil, LJ, et al. Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms. Clin Lymphoma Myeloma Leuk 2014; 14: 460–467.e462.
Google Scholar | Crossref | Medline22. Abdulla, M, Hollander, P, Pandzic, T, et al. Cell-of-origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B-cell lymphoma. Am J Hematol 2020; 95: 57–67.
Google Scholar | Crossref | Medline23. Cho, I, Yoon, N, Hyeon, J, et al. Comparison of the lymph2Cx assay and hans algorithm in determining the cell-of-origin of diffuse large B-cell lymphomas, not otherwise specified. Appl Immunohistochem Mol Morphol 2020; 28: 731–740.
Google Scholar | Crossref | Medline24. Choi, WWL, Weisenburger, DD, Greiner, TC, et al. A new immunostain algorithm classifies diffuse large B-Cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009; 15: 5494–5502.
Google Scholar | Crossref | Medline | ISI25. Muris, J, Meijer, C, Vos, W, et al. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol 2006; 208: 714–723.
Google Scholar | Crossref | Medline | ISI26. Nyman, H, Jerkeman, M, Karjalainen-Lindsberg, ML, et al. Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP. Mod Pathol 2009; 22: 1094–1101.
Google Scholar | Crossref | Medline27. Natkunam, Y, Farinha, P, Hsi, ED, et al. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol 2008; 26: 447–454.
Google Scholar | Crossref | Medline28. Visco, C, Li, Y, Xu-Monette, ZY, et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia 2012; 26: 2103–2113.
Google Scholar | Medline | ISI29. Meyer, PN, Fu, K, Greiner, TC, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 2011; 29: 200–207.
Google Scholar | Crossref | Medline | ISI30. Colomo, L, López-Guillermo, A, Perales, M, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101: 78–84.
Google Scholar | Crossref | Medline | ISI31. Perfecto-Avalos, Y, Garcia-Gonzalez, A, Hernandez-Reynoso, A, et al. Discriminant analysis and machine learning approach for evaluating and improving the performance of immunohistochemical algorithms for COO classification of DLBCL. J Transl Med 2019; 17: 198.
Google Scholar | Crossref | Medline32. de Jong, D, Xie, W, Rosenwald, A, et al. Retracted: immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium). J Clin Oncol 2007; 25: 805–812.
Google Scholar | Crossref | Medline33. Salles, G, de Jong, D, Xie, W, et al. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood 2011; 117: 7070–7078.
Google Scholar | Crossref | Medline34. Yan, W-H, Jiang, X-N, Wang, W-G, et al. Cell-of-origin subtyping of diffuse large B-cell lymphoma by using a qPCR-based gene expression assay on formalin-fixed paraffin-embedded tissues. Front Oncol 2020; 10: 803–803.
Google Scholar | Crossref | Medline35. Xu-Monette, ZY, Zhang, H, Zhu, F, et al. A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL. Blood Adv 2020; 4: 3391–3404.
Google Scholar | Crossref | Medline36. Lossos, IS, Czerwinski, DK, Alizadeh, AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. New Engl J Med 2004; 350: 1828–1837.
Google Scholar | Crossref | Medline | ISI37. Malumbres, R, Chen, J, Tibshirani, R, et al. Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood 2008; 111: 5509–5514.
Google Scholar | Crossref | Medline | ISI38. Tekin, N, Omidvar, N, Morris, TP, et al. Protocol for qRT-PCR analysis from formalin fixed paraffin embedded tissue sections from diffuse large b-cell lymphoma: validation of the six-gene predictor score. Oncotarget 2016; 7: 83319–83329.
Google Scholar | Crossref | Medline39. Alizadeh, AA, Gentles, AJ, Alencar, AJ, et al. Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Blood 2011; 118: 1350–1358.
Google Scholar | Crossref | Medline | ISI40. Green, TM, Jensen, AK, Holst, R, et al. Multiplex polymerase chain reaction-based prognostic models in diffuse large B-cell lymphoma patients treated with R-CHOP. Br J Haematol 2016; 174: 876–886.
Google Scholar | Crossref | Medline41. Reddy, A, Zhang, J, Davis, NS, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell 2017; 171: 481–494.e415.
Google Scholar | Crossref | Medline42. Schmitz, R, Wright, GW, Huang, DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. New Engl J Med 2018; 378: 1396–1407.
Google Scholar | Crossref | Medline43. Chapuy, B, Stewart, C, Dunford, AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 2018; 24: 679–690.
Google Scholar | Crossref | Medline44. Lacy, SE, Barrans, SL, Beer, PA, et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. Blood 2020; 135: 1759–1771.
Google Scholar | Crossref | Medline45. Wright, GW, Huang, DW, Phelan, JD, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell 2020; 37: 551–568.e514.
Google Sch